Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 51 of 80 for:    "Cervix Disease" | "Vaccines"

Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02689726
Recruitment Status : Terminated (Lack of efficacy in European Phase 2 study)
First Posted : February 24, 2016
Last Update Posted : December 2, 2016
Sponsor:
Collaborator:
PPD
Information provided by (Responsible Party):
Genticel

Brief Summary:
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL.

Condition or disease Intervention/treatment Phase
HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL Drug: GTL001+ Drug: Aldara Phase 1

Detailed Description:
This is an outpatient, open-label study. After a screening period of up to 4 weeks, all eligible subjects will receive 2 doses, 6 weeks apart, of GTL001 Powder reconstituted with water for injection. GTL001 will be adjuvanted with Aldara, 5% imiquimod cream, applied to the injection site 15 minutes and 24 hours after each vaccination. The follow-up period is 12 weeks from the first injection. The duration of the study is defined for each subject as the date that signed, written informed consent is provided through the last follow-up visit. Total duration of subject participation is approximately 16 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL
Study Start Date : August 2015
Actual Primary Completion Date : August 2016
Actual Study Completion Date : August 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Imiquimod

Arm Intervention/treatment
Experimental: GTL001 + Aldara, 5% imiquimod cream
2 doses, 6 weeks apart, GTL001 will be adjuvanted with Aldara, 5% imiquimod cream, applied to the injection site 15 minutes and 24 hours after each vaccination
Drug: GTL001+
Drug: Aldara
5% imiquimod cream




Primary Outcome Measures :
  1. Incidence of local and systemic reactions recorded on diary cards as a measure of safety and tolerability [ Time Frame: 14-day period following an injection ]
    To assess the tolerability, with respect to vaccine-specific local and systemic reactions, of GTL001 adjuvanted with imiquimod in women in 2 age cohorts: 25 to 50 years, inclusive, and 51 to 65 years, inclusive. The diary cards will include local abd systemic reactions to the adjuvant, medications taken with start and stop dates, and other unsolicited symptoms/complaints, including start and stop dates.


Secondary Outcome Measures :
  1. Level of anti-CyaA serum as a measure of cellular and humoral Immunogenicity [ Time Frame: 12 weeks ]
    Measured by enzyme-linked immunoabsorbent assay (ELISA) at weeks 0,2,6,8, and 12 (Visits 1,2,3,4, and 5, respectively) To assess the cellular and humoral immunogenicity of GTL001 adjuvanted with imiquimod in the 2 age cohorts.

  2. Percentage of subjects with anti-CyaA serum antibody response as a measure of cellular and humoral immunogenicity [ Time Frame: 12 weeks ]
    Measured at weeks 2,6,8, and 12 (Visits 2,3,4, and 5, respectively) To assess the cellular and humoral immunogenicity of GTL001 adjuvanted with imiquimod in the 2 age cohorts.

  3. Specific responses to HPV 16 and HPV 18 E7 Ag stimulation as a measure of cellular and humoral Immunogenicity [ Time Frame: 12 weeks ]
    Measured at weeks 0,2,6,8, and 12 (Visits 1,2,3,4, and 5, respectively) To assess the cellular and humoral immunogenicity of GTL001 adjuvanted with imiquimod in the 2 age cohorts.

  4. Percentage of subjects with positive specific response to HPV 16 and/or HPV 18 E7 stimulation as a measure of cellular and humoral Immunogenicity [ Time Frame: 12 weeks ]
    To assess the cellular and humoral immunogenicity of GTL001 adjuvanted with imiquimod in the 2 age cohorts.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Females between the ages of 25 and 65 years, inclusive, at the time of screening.
  2. Subject is in generally good health based on medical history and on clinically acceptable results, in the judgment of the investigator, on the following assessments: physical examination, vital signs, clinical chemistry, and hematology.
  3. Cervical HPV 16 and/or 18 infection confirmed by cobas® HPV Test (Roche Molecular Systems, Inc) real-time polymerase chain reaction (RT PCR) assay at screening.
  4. Cervical cytological evaluation with a normal, ASCUS, or LSIL result.
  5. Subjects of childbearing potential must use effective contraception at the time of GTL001 injection and for at least 12 months after the first vaccination. Effective methods of birth control include those that result in a low failure rate (ie, less than 1% per year) when used consistently and correctly, such as implants, injectable, combined oral contraceptives, desogestrel only pill, levonorgestrel-releasing intrauterine system, intrauterine devices, vasectomized partner, and true sexual abstinence. Subjects not of childbearing potential include those who are surgically sterile or postmenopausal (no menses for the previous 12 months).
  6. Subject is capable of understanding the written informed consent, provides signed and witnessed written informed consent, and agrees to comply with protocol requirements.
  7. In the opinion of the investigator, the subject is able to comply with the protocol and has a high probability of completing the study.

Exclusion Criteria:

  1. Current or history of untreated high-grade cervical lesion (either CIN2 or CIN3).
  2. Current or history of cervical, vulvar, or vaginal cancer.
  3. Prior exposure to HPV prophylactic vaccine, regardless of number of doses received, or participation in another HPV vaccination clinical trial.
  4. Current acute or chronic disease, other than HPV 16/18 infection, which would be expected to interfere with the protocol-defined evaluations.
  5. Clinically significant gynecological abnormalities that could interfere with study procedures (eg, prolapse, severe vaginal atrophy, myoma, hysterectomy) in the judgment of the investigator.
  6. Malignancy, or treatment for malignancy, within the previous 2 years, with the exception of basal cell or squamous cell carcinoma of the skin.
  7. Clinically important abnormalities in the physical examination or laboratory tests during the screening period (ie, hemoglobin level <9.5 g/dL, white blood cells <2500 cells/mm3, aspartate aminotransferase and/or alanine aminotransferase ≥1.5 × the upper limit of normal [ULN], creatinine ≥1.25 × ULN, alkaline phosphatase ≥2 × ULN, and total bilirubin >ULN).
  8. Administration of any live viral vaccine within 3 months or any inactivated (nonlive) vaccine within 2 weeks prior to screening.
  9. Primary or secondary systemic immunosuppression (defined as prolonged [≥7 days] use of corticosteroids that is ≥20 mg/day of prednisone equivalent or any other immunosuppressive drug).
  10. History of severe allergy requiring hospital care or history of severe asthma requiring oral or parenteral drug management in the last year.
  11. Known hypersensitivity to imiquimod.
  12. History of a severe reaction to any drug or vaccination.
  13. Medical condition with clinical and/or biological consequences judged by the investigator to be incompatible with ID vaccination.
  14. History of, or positive test results at screening for, human immunodeficiency virus, hepatitis B virus surface Ag, or hepatitis C virus.
  15. Current episode of symptomatic vaginal or genital infection.
  16. Current episode or history of genital herpes.
  17. Subject is pregnant or lactating/breastfeeding.
  18. Use of any investigational drug within 30 days before screening or current participation in another clinical trial.
  19. History of recent (within 1 year) alcohol/drug abuse.
  20. Employee or family member of the investigator or study site personnel.
  21. Enrollment goals have been reached in the subject's age cohort

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02689726


Locations
Layout table for location information
United States, Kentucky
University of Louisville
Louisville, Kentucky, United States, 40208
United States, North Carolina
Wake Research Associates, LLC
Raleigh, North Carolina, United States, 27612
United States, Ohio
Clinical Research Advantage, Inc./ Columbus Obstetricians and Gynecology, Inc.
Columbus, Ohio, United States, 43213
United States, Pennsylvania
Planned Parenthood Southeastern Pennsylvania
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Genticel
PPD

Layout table for additonal information
Responsible Party: Genticel
ClinicalTrials.gov Identifier: NCT02689726     History of Changes
Other Study ID Numbers: PC10VAC05
016462 ( Registry Identifier: Serial No.: 0001 )
First Posted: February 24, 2016    Key Record Dates
Last Update Posted: December 2, 2016
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Diseases
Atypical Squamous Cells of the Cervix
Uterine Cervical Dysplasia
Precancerous Conditions
Neoplasms
Uterine Diseases
Genital Diseases, Female
Imiquimod
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic
Antineoplastic Agents
Interferon Inducers